Fredrik Dalborg is appointed new President and CEO of AddLife
The Board of Directors of AddLife AB (publ) has today appointed Fredrik Dalborg as the new President and CEO of AddLife. Fredrik Dalborg succeeds Kristina Willgård, who previously announced her decision to resign no later than during the fourth quarter of 2022, when Fredrik Dalborg is expected to take over.
Fredrik Dalborg is a very well-qualified and business-oriented leader with international experience deeply rooted in Life Science. Fredrik leaves the listed company XVIVO Perfusion where he is part of the management team as Managing Director North America. Prior to that, Fredrik was President and CEO of Etac Group and listed Boule Diagnostics. In addition, he has held several senior positions in Life Science companies such as Terumo and Gambro. He has a master's degree in economics from the Stockholm School of Economics.
Johan Sjö, Chairman of the Board, says: “We are very pleased to welcome Fredrik Dalborg as the new CEO of AddLife. Under Kristina Willgård's leadership, the company has had a very strong growth journey where both sales and earnings have multiplied, and we on the Board are convinced that Fredrik has the leadership skills and experience required to take AddLife to the next level and continue AddLife's strong development.”
Kristina Willgård comments: “I am very grateful and proud that I have had the opportunity to lead AddLife's growth journey, from the spin-off from Addtech 2016 to a Large Cap company on Nasdaq Stockholm 2022. AddLife is today a leading European Life Science company in selected niches with a well-established corporate culture, where committed employees do a fantastic job every day. We have never been stronger and it feels very good to hand over the helm to Fredrik, as he has the right experience to expand into the next phase.”
Fredrik Dalborg, incoming CEO says: “I have followed AddLife with great interest for a long time and am very impressed with what the team has achieved under Kristina's leadership. The corporate culture and management philosophy that AddLife stands for is completely in line with my own personal values and I am honored and happy to be part of the AddLife team. AddLife has established a strong position in the European market and I look forward to, together with the team, to further develop the company to the next level.”
Stockholm, 21 April 2022
AddLife AB (publ)
For further information, please contact:
Johan Sjö, Chairman of the Board AddLife AB, +46 070 799 40 44
Kristina Willgård, CEO, AddLife AB, +46 (0)705 10 12 23
AddLife is an independent European player in Life Science that offers high-quality products, services and consulting to both the private and public sectors. AddLife has about 2,200 employees in around 80 operating subsidiaries, which operate under their own brands. The Group has annual sales of approximately SEK 8 billion. AddLife is listed on the NASDAQ Stockholm stock exchange.
This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 21 April 2022 at 13.00 p.m. (CET).